Wedbush Issues Positive Estimate for ZNTL Earnings

Key Points

• Analysts at Wedbush have increased their Q3 2025 earnings estimates for Zentalis Pharmaceuticals to ($0.47) EPS, while maintaining a "Neutral" rating and a price target of $4.00.
• Institutional investors have significantly increased their stakes in Zentalis, with Millennium Management boosting its holdings by over 220% in the first quarter of 2023.
• The average rating for Zentalis Pharmaceuticals is currently at "Moderate Buy", with a consensus target price of $8.20 set by investment analysts.

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Stock analysts at Wedbush upped their Q3 2025 EPS estimates for Zentalis Pharmaceuticals in a report released on Wednesday, August 6th. Wedbush analyst R. Driscoll now anticipates that the company will earn ($0.47) per share for the quarter, up from their previous estimate of ($0.58). Wedbush currently has a "Neutral" rating and a $4.00 target price on the stock. The consensus estimate for Zentalis Pharmaceuticals' current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Zentalis Pharmaceuticals' Q4 2025 earnings at ($0.34) EPS, FY2025 earnings at ($1.81) EPS, FY2026 earnings at ($1.41) EPS, FY2027 earnings at ($1.14) EPS, FY2028 earnings at ($0.51) EPS and FY2029 earnings at ($0.01) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.56) by $0.19.

A number of other equities research analysts have also weighed in on ZNTL. Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Saturday. HC Wainwright upgraded shares of Zentalis Pharmaceuticals to a "strong-buy" rating in a report on Thursday, August 7th. Finally, Wells Fargo & Company lowered their target price on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an "equal weight" rating on the stock in a report on Thursday, August 7th. Four analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $8.20.

Zentalis Pharmaceuticals Trading Up 6.0%

Shares of ZNTL traded up $0.09 on Monday, reaching $1.50. The company's stock had a trading volume of 496,995 shares, compared to its average volume of 1,237,260. Zentalis Pharmaceuticals has a twelve month low of $1.01 and a twelve month high of $5.44. The stock has a market capitalization of $107.85 million, a PE ratio of -0.66 and a beta of 1.71. The firm has a fifty day moving average of $1.38 and a 200-day moving average of $1.54.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC grew its position in shares of Zentalis Pharmaceuticals by 220.6% during the 1st quarter. Millennium Management LLC now owns 3,069,514 shares of the company's stock valued at $4,881,000 after acquiring an additional 2,111,951 shares during the period. Acadian Asset Management LLC grew its position in shares of Zentalis Pharmaceuticals by 4.7% during the 2nd quarter. Acadian Asset Management LLC now owns 2,799,020 shares of the company's stock valued at $3,241,000 after acquiring an additional 124,985 shares during the period. Almitas Capital LLC grew its position in shares of Zentalis Pharmaceuticals by 5.2% during the 1st quarter. Almitas Capital LLC now owns 1,710,921 shares of the company's stock valued at $2,720,000 after acquiring an additional 84,025 shares during the period. Tybourne Capital Management HK Ltd. grew its position in shares of Zentalis Pharmaceuticals by 53.7% during the 2nd quarter. Tybourne Capital Management HK Ltd. now owns 1,478,152 shares of the company's stock valued at $1,715,000 after acquiring an additional 516,666 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Zentalis Pharmaceuticals by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 1,312,964 shares of the company's stock valued at $3,979,000 after acquiring an additional 20,864 shares during the period.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.